Fertility clinics using peptide therapies must navigate a layered FDA regulatory framework. The rules differ based on whether a peptide is FDA-approved, compounded, or investigational. Getting this wrong can result in warning letters, injunctions, or criminal charges.
Introduction: FDA Oversight Is Not Optional
The FDA has authority over virtually every drug used in a clinical setting, and peptides are no exception. For fertility clinics, this matters a great deal. Many popular peptide therapies exist in a gray zone between approved drugs and compounded preparations.
Understanding exactly where your peptide therapies fall in the FDA's framework is the first step to building a compliant clinic. This post walks through the rules in plain language so your team can act with confidence.
As Sarah Sellers, PharmD, FDA Regulatory Counsel, noted in the American Journal of Health-System Pharmacy (2024): "Compounding pharmacies operating under Section 503A have a critical limitation: they cannot distribute compounded drugs interstate without violating federal law, yet many do exactly that."
How the FDA Classifies Peptides
The FDA does not have a single category called "peptides." Instead, peptides are regulated as drugs, biologics, or new drug substances depending on their structure, source, and intended use.
Most synthetic peptides used in fertility clinics are regulated as drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This means they must either be FDA-approved, lawfully compounded, or used under an approved investigational new drug (IND) application.
According to the FDA, there are currently over 100 peptide-based drugs approved for use in the United States. However, the majority of peptides being offered in wellness and fertility settings are not among these approved products, which places them under heavy scrutiny.
Since 2019, the FDA has issued more than 70 warning letters to compounding pharmacies producing peptide products that were never evaluated for safety or efficacy under an approved drug application.
FDA-Approved Peptides in Fertility Medicine
Some peptides used in reproductive medicine have full FDA approval. These include:
| Peptide / Drug Name | FDA-Approved Use in Fertility |
|---|---|
| Leuprolide (Lupron) | GnRH agonist for ovarian suppression |
| Ganirelix (Antagon) | GnRH antagonist for IVF protocols |
| Cetrorelix (Cetrotide) | GnRH antagonist for controlled ovarian stimulation |
| Follitropin alfa (Gonal-F) | Gonadotropin for follicle stimulation |
For these drugs, fertility clinics must follow the FDA-approved labeling. Off-label use is permitted for licensed prescribers, but the clinical rationale must be documented in the patient record.
Compounded Peptides: A Closer Look at the Rules
Many fertility clinics source peptide therapies from compounding pharmacies because approved drugs are not available in the right form, dose, or combination. Compounding is legal, but heavily regulated.
503A Pharmacies
These are traditional compounding pharmacies. They can only compound drugs for individual patients based on a valid prescription. They are regulated primarily by state pharmacy boards, with some federal oversight from the FDA.
503B Outsourcing Facilities
These facilities are registered with the FDA. They can compound larger batches without individual patient prescriptions. They face more rigorous FDA inspection and quality standards.
For fertility clinics, using a 503B facility often provides more consistency and a stronger compliance record. However, 503A pharmacies are also legal as long as the prescription and patient-specific requirements are met.
Clinics must verify pharmacy credentials before ordering. The FDA maintains a public list of registered 503B outsourcing facilities at fda.gov. According to the FDA's drug compounding page, facilities that violate current good manufacturing practices (cGMP) face mandatory recalls and possible injunctions.
The Problem With Peptides on the FDA Bulk Drug Substances List
The FDA maintains lists of bulk drug substances that can and cannot be used in compounding. This is critical for fertility clinics.
Some peptides commonly marketed for fertility and wellness purposes are NOT on the FDA's approved bulk drug substance list for compounding. Using these compounds puts your clinic in direct violation of federal law, even if the compounding pharmacy claims they are legal.
Before offering any compounded peptide therapy, verify that the bulk substance is:
- On the FDA's 503A or 503B nominated substances list with a positive determination, OR
- An FDA-approved drug being compounded in a different form or strength, OR
- Covered under a current IND application at your facility
This step alone prevents the most serious FDA violations fertility clinics face.
Investigational New Drug (IND) Applications
If a fertility clinic wants to use a peptide that is not yet approved or lawfully compounded, the only legal path is through an IND application.
An IND allows a researcher or institution to administer an unapproved drug to human subjects as part of a clinical investigation. This process requires:
- Detailed protocol submission to the FDA
- IRB (Institutional Review Board) approval
- Ongoing safety reporting to the FDA
- Patient informed consent that explains the investigational nature of the treatment
Most fertility clinics are not set up for IND-level compliance. If you are considering this path, you will need a regulatory affairs specialist with IND experience on your team or on retainer.
For expert support in navigating regulatory filings, review our resource on peptide drug regulatory outsourcing.
FDA Enforcement Actions: What Gets Clinics in Trouble
The FDA has taken enforcement action against clinics and compounders offering unapproved peptide therapies. Common violations include:
- Selling or distributing unapproved new drugs
- Using bulk drug substances not on approved lists
- Failing to follow cGMP standards
- Making unsubstantiated efficacy claims about peptide therapies
- Importing peptides from foreign sources without proper authorization
FDA warning letters are public and permanent. They signal to patients, investors, and partners that your clinic has compliance problems. More serious violations can result in federal injunctions, civil penalties, or criminal prosecution.
Before sourcing any compounded peptide, verify whether your pharmacy is a registered 503B outsourcing facility on the FDA's public database, because 503A pharmacies cannot legally supply your clinic without a patient-specific prescription in hand.
Off-Label Use: What Is and Is Not Allowed
Off-label prescribing is a legal practice in the United States. A licensed physician can prescribe an FDA-approved drug for a use not listed on its label. This includes using certain approved peptide drugs in fertility protocols not specifically covered by the label.
What is NOT allowed:
- Promoting off-label uses in marketing materials
- Making claims that off-label use has been proven effective without clinical evidence
- Using unapproved drug substances under the claim of off-label use
Clinics often confuse off-label use of approved drugs with the use of entirely unapproved substances. These are very different legal situations.
Labeling and Advertising Rules
The FDA also regulates how fertility clinics can talk about peptide therapies. If your clinic's website, brochures, or social media describe a peptide therapy in a way that constitutes drug promotion, the FDA may treat your clinic as a drug manufacturer or distributor.
Avoid making specific medical claims about unapproved peptides. Do not use language that implies the FDA has evaluated or approved a therapy that it has not. Work with a healthcare attorney to review all patient-facing materials.
Staying Current With FDA Guidance
FDA guidance on peptides and compounding is updated regularly. Clinics must monitor:
- FDA Drug Safety Communications
- Compounding guidance updates on fda.gov
- 503A and 503B bulk substance list changes
- FDA MedWatch safety alerts for peptide-related adverse events
Assign one person at your clinic to own this responsibility. Alternatively, work with a regulatory affairs consultant who provides ongoing monitoring as part of their service.
For clinics that want structured support in this area, our guide on peptide GMP compliance consulting outlines how external consultants can help you stay current.
Key Regulatory Steps for Fertility Clinics
Here is a simplified compliance checklist for FDA requirements:
| Action Item | Priority |
|---|---|
| Verify all peptides are approved or lawfully compounded | Critical |
| Confirm pharmacy is 503A or 503B licensed | Critical |
| Review bulk substance eligibility for compounded products | Critical |
| Document clinical rationale for all off-label prescriptions | High |
| Review all patient-facing marketing for drug promotion issues | High |
| Assign a regulatory monitoring owner or consultant | High |
| Train prescribers on FDA prescribing requirements | Medium |
| Conduct annual internal regulatory review | Medium |
Expert Perspective
"The FDA has made it very clear that it is watching the compounded peptide space closely. Fertility clinics that rely on compounded therapies need to treat their pharmacy vendor relationships like compliance relationships, not just supply chain decisions. A bad pharmacy partner can bring your entire program down." - Regulatory Affairs Professional, Reproductive Medicine Conference (paraphrased from public presentation)
Every peptide used in your fertility clinic must fall cleanly into one of three FDA categories (approved, lawfully compounded, or under an IND), and misclassifying even one product exposes your practice to enforcement action.
Frequently Asked Questions
Are peptide therapies FDA-approved for fertility treatments? Some peptides used in fertility medicine are FDA-approved, such as GnRH agonists and antagonists. Many other peptides used in wellness-adjacent fertility programs are not FDA-approved and must be legally compounded or used under an IND.
Can a fertility clinic legally offer compounded peptide injections? Yes, if the compounding pharmacy is properly licensed (503A or 503B), the bulk drug substance is permitted, and the prescription meets all legal requirements.
What happens if the FDA finds a fertility clinic using unapproved peptides? The FDA may issue a warning letter, require product seizure, pursue injunctive relief, or refer the case for criminal prosecution depending on severity.
How does a fertility clinic verify a compounding pharmacy's FDA status? Search the FDA's database of registered 503B outsourcing facilities at fda.gov. For 503A pharmacies, verify licensure through your state pharmacy board.
What is the difference between off-label use and using an unapproved drug? Off-label use applies to FDA-approved drugs prescribed for a purpose outside the label. Using a substance that has never been FDA-approved at all is a different situation and is not protected by off-label prescribing rights.
Do fertility clinics need FDA approval to offer peptide therapy programs? No, clinics do not need approval themselves, but the drugs or substances they use must comply with FDA regulations. Prescribers must follow applicable prescribing and dispensing laws.
Conclusion
FDA regulations for peptide therapy at fertility clinics are detailed and strictly enforced. The key is knowing which category each of your therapies falls into and making sure every step of your process, from pharmacy sourcing to patient documentation, meets federal standards.
The clinics that avoid FDA trouble are the ones that build compliance into their operations from day one. They verify their pharmacy partners, train their prescribers, and monitor for regulatory updates. They do not wait for an inspection or a warning letter to take action.
If your clinic is expanding into peptide therapies, now is the time to get your regulatory framework in order.
Topics
Jennifer Walsh
Senior Healthcare Staffing Consultant
RN, BSN | 13 years placing clinical professionals in wellness practices
Registered nurse and staffing specialist who has placed over 400 clinical professionals across peptide therapy, hormone optimization, and integrative medicine clinics. Expertise in credentialing and retention strategy.
Reviewed by Jennifer Walsh, RN, April 2026